MedMira receives CE mark for Multiplo® Complete Syphilis (TP/nTP) Antibody Test

Halifax, Nova Scotia, 12 May, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the achievement of another milestone in its regulatory strategy by receiving the CE mark for its Multiplo® Complete Syphilis (TP/nTP) Antibody Test (Multiplo® TP/nTP). This approval allows the Company to further strengthen its product offering in all markets accepting the CE […]
MedMira receives the CE mark for its Reveal® TP (Syphilis) and starts clinical trials in Canada

Halifax, Nova Scotia, 9 March, 2022 – Today, MedMira Inc. (MedMira) (TSXV: MIR) launches its Reveal® TP (Syphilis) product in Europe and gets clinical trial underway in Canada. The Company received the CE mark today and is now available in Europe and any countries accepting the CE mark. Furthermore, the Company continues their work on […]
Corporate update

In the second financial quarter of FY2022, MedMira continued its strategic plan to focus its own product portfolio on the two fastest growing disease segments in the IVD rapid test market. Furthermore, the Company continued its work with public and private partners to develop new potential tests based on its Rapid Vertical Flow (RVF) Technology™ […]
MedMira’s COVID-19 Tests – for ANY STAGE

Download the MedMira COVID-19 testing overview
Product and Regulatory Update on MedMira’s COVID-19 Product Family

Halifax, Nova Scotia, 03 March, 2021 – MedMira Inc. (MedMira) (TSXV: MIR) announces the expansion of its product portfolio and outlines the company’s COVID-19 market and regulatory plan. MedMira has utilized its patented Rapid Vertical Flow™ (RVF™) technology and developed the company’s first rapid antigen test,VYRA CoV-2 Antigen Test (VYRA CoV-2), designed to detect SARS-CoV-2 […]
MedMira Announces Product Update

Halifax, Nova Scotia, 30 December, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR), is pleased to announce its validated REVEALCOVID-19™ PLUS Total Antibody Test for the detection of total antibodies against both the Nucleocapsid and Spike regions of the SARS-CoV-2. REVEALCOVID-19™ PLUS Total Antibody Test is an update to MedMira’s REVEALCOVID-19™ Total Antibody Test that […]
MedMira reports additional independent performance evaluation results of REVEALCOVID-19™

Halifax, Nova Scotia, 7th of October, 2020 – Today, MedMira Inc. (MedMira) (TSXV: MIR) announces the results of the latest independent performance evaluation results of REVEALCOVID-19TM Total Antibody Test. The study was carried out at a state licensed, state-of-the-art hospital in Texas (between June and September 2020). This facility utilizes a patient-centred model to provide […]
MedMira Announces Update on Development of Point-of-Care Antibody Test

Halifax, Nova Scotia, 15th of April, 2020 – MedMira Inc. (MedMira) (TSXV: MIR), announced today that it has completed the development of the serological Point-of-Care (POC) testing solution with immediate result. Based on MedMira’s unique and patented Rapid Vertical Flow™ (RVF) technology, the newly developed REVEALCOVID-19™ delivers immediate results without the need for any additional […]